Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10271978" target="_blank" >RIV/00064203:_____/14:10271978 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/14:10271978 RIV/00216208:11140/14:10271978 RIV/00669806:_____/14:10271978
Výsledek na webu
<a href="http://dx.doi.org/10.1007/s00508-014-0508-6" target="_blank" >http://dx.doi.org/10.1007/s00508-014-0508-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00508-014-0508-6" target="_blank" >10.1007/s00508-014-0508-6</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study
Popis výsledku v původním jazyce
Glucose variability combined with glycosylated hemoglobin (HbA1c) assessments more reliably represents the level of glycemic control. The study was aimed to compare blood glucose variability with insulin glargine vs. neutral protamine Hagedorn (NPH) in patients with type 2 diabetes mellitus using a continuous glucose-monitoring system (CGMS), in patients treated with basal insulin using stable dose of oral antidiabetic agents and HbA1c in the range of 4.5-8.0 % International Federation of Clinical Chemistry (IFCC) units. [6.2-9.4 % Diabetes Control and Complications Trial (DCCT) units]. This was a multicenter, prospective, open-label, single-arm study in patients (N = 116) treated for a parts per thousand yenaEuro parts per thousand 2 months with NPH and metformin combined with sulfonylurea or glinide. Glucose variability was measured after a 4-week NPH treatment phase and after a subsequent 12-week glargine treatment phase using CGMS. Based on 72-hour CGMS, glucose variability was ass
Název v anglickém jazyce
Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study
Popis výsledku anglicky
Glucose variability combined with glycosylated hemoglobin (HbA1c) assessments more reliably represents the level of glycemic control. The study was aimed to compare blood glucose variability with insulin glargine vs. neutral protamine Hagedorn (NPH) in patients with type 2 diabetes mellitus using a continuous glucose-monitoring system (CGMS), in patients treated with basal insulin using stable dose of oral antidiabetic agents and HbA1c in the range of 4.5-8.0 % International Federation of Clinical Chemistry (IFCC) units. [6.2-9.4 % Diabetes Control and Complications Trial (DCCT) units]. This was a multicenter, prospective, open-label, single-arm study in patients (N = 116) treated for a parts per thousand yenaEuro parts per thousand 2 months with NPH and metformin combined with sulfonylurea or glinide. Glucose variability was measured after a 4-week NPH treatment phase and after a subsequent 12-week glargine treatment phase using CGMS. Based on 72-hour CGMS, glucose variability was ass
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FB - Endokrinologie, diabetologie, metabolismus, výživa
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Wiener Klinische Wochenschrift
ISSN
0043-5325
e-ISSN
—
Svazek periodika
126
Číslo periodika v rámci svazku
7-8
Stát vydavatele periodika
AT - Rakouská republika
Počet stran výsledku
10
Strana od-do
228-237
Kód UT WoS článku
000335170200008
EID výsledku v databázi Scopus
—